The Pharmaceutical Benefits Advisory Committee (PBAC) has approved a PBS listing for ralatrexate (Folotyn) for the treatment of Peripheral T-Cell Lymphoma. At its November 2017 meeting the PBAC supported a request from MundiPharma for a Section 100 listing for the treatment of patients who are refractory to, or have relapsed following, first line chemotherapy. The ...
New drugs for blood cancers get approval for PBS listing
By Michael Woodhead
16 Feb 2018